Journal
TRANSLATIONAL ONCOLOGY
Volume 14, Issue 8, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2021.101123
Keywords
PEAC; Immunohistochemistry; Mutation analysis; Diagnosis; Prognosis
Categories
Funding
- Zhejiang Province Medical Science and Technology Project [2020ZH001]
- CSCO Haosen Cancer Research Foundation [Y-HS2017-044]
Ask authors/readers for more resources
PEAC is an exceptionally rare subtype of lung cancer with features similar to colorectal adenocarcinoma. It has unique mutation expression and immune characteristics, with potential for targeted therapy in the future.
Pulmonary enteric adenocarcinoma (PEAC) is an exceptionally rare subtype of non-small cell lung cancer (NSCLC). It is characterized by pathological features similar to those of colorectal adenocarcinoma. Most patients with PEAC have almost no special clinical manifestations, and it is often difficult to differentiate from metastatic colorectal adenocarcinoma (MCRC). As a special type of lung adenocarcinoma, PEAC has unique mutation expres-sion and immune characteristics; its mutation profile shows higher Kirsten rat sarcoma viral oncogene (KRAS), human epidermal growth factor receptor-2 (HER2) , DNA mismatch repair(MMR) mutation rates, and much lower epidermal growth factor receptor (EGFR) rate. So in the future, targeted therapy may tend to be a new light in the treatment of PEAC. As for immunohistochemistry (IHC), CDX-2, villin, and CK7 are significantly positive in PEAC. This review focuses on the pathologic features, immunohistochemical examination, mutation analysis, diagnosis, treatment, and prognosis of PEAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available